http://lookfordiagnosis.com
English
Spanish
Italian
Portuguese
French
Swedish
Viamet Announces Appointment of Amir Tavakkol, Ph.D., as Chief Development ...
The Company's lead product candidate, VT-1161, is an oral agent that is being developed for the treatment of recurrent vulvovaginal candidiasis, or RVVC, a highly prevalent mucosal infection for which there are no approved therapies in the United ...
MarketWatch - Tue, 22 Jul 2014 06:52

Astellas Isavuconazole Gets QIDP for Invasive Candidiasis
Astellas Pharma, Inc.'s (ALPMY) isavuconazole received Qualified Infectious Disease Product (QIDP) designation from the FDA for the treatment of invasive candidiasis. The QIDP status means that isavuconazole will get priority review besides enjoying a ...
Zacks.com - Thu, 17 Jul 2014 13:48

FDA Grants Infectious Disease Designation to Invasive Candidiasis Drug
HCPLive - Thu, 17 Jul 2014 09:07

Basilea reports that isavuconazole received QIDP designation from US FDA for ...
Wall Street Journal - Wed, 16 Jul 2014 09:07

US FDA designates isavuconazole as Qualified Infectious Disease Product to ...
pharmabiz.com - Wed, 16 Jul 2014 08:56

FDA Grants Astellas Qualified Infectious Disease Product Designation for ...
PR Newswire (press release) - Wed, 16 Jul 2014 08:56

What You Missed From The FDA Last Week— July 14-18, 2014
Astellas Pharma announced that the FDA has designated isavuconazole a Qualified Infectious Disease Product (QIPD). Isavuconazole is a once-daily intravenous and oral antifungal indicated for the treatment of invasive candidiasis. This designation ...
Pharmaceutical Online (press release) - Mon, 21 Jul 2014 06:18

FDA designates isavuconazole QIDP drug
Astellas recently announced that the FDA has designated its antifungal agent isavuconazole as a qualified infectious disease product, or QIDP, for the treatment of invasive candidiasis. Under the 2012 Generating Antibiotic Incentives Now (GAIN) Act ...
Healio - Fri, 18 Jul 2014 14:00

BRIEF- Basilea Pharmaceutica announces isavuconazole received QIDP ...
July 16(Reuters) - Basilea Pharmaceutica AG : * Says U.S. Food and Drug Administration designated. Isavuconazole as Qualified Infectious Disease Product (QIDP) for oral and intravenous treatment of invasive candidiasis Source text for Eikon: Further ...
Reuters - Thu, 17 Jul 2014 00:43

Viamet Reports Additional Positive Interim Results of Phase 2 Study of VT-1161 ...
... Inc. today reported additional positive interim results from its ongoing Phase 2a study of VT-1161, the Company's lead novel, oral antifungal compound, in patients with moderate to severe acute vulvovaginal candidiasis (AVVC), commonly known as ...
Business Wire (press release) - Thu, 10 Jul 2014 12:30

Looking back: healing hands
Many North Carolina residents believed people who never met their fathers could cure thrush by holding the child and blowing into its mouth. Once they blew into the child's mouth, the child would be cured within a day or two. Although this seems a ...
Myhorrynews - Mon, 07 Jul 2014 13:31

GSK and Theravance Announce Submission to US Regulatory Authorities for ...
Oropharyngeal candidiasis has occurred in patients treated with Breo Ellipta. Patients should rinse their mouth with water without swallowing after inhalation to help reduce this risk. An increase in the incidence of pneumonia has been observed in ...
PipelineReview.com (press release) - Mon, 30 Jun 2014 09:41


1  2  3  4  5  6  7  8    ->

Last update: April 2009
Statistics